Cytogen Corp (CYTO) said an investigational new drug application for its lead therapeutic candidate targeting prostate-specific membrane antigen, CYT-500, has been approved by the Food and Drug Administration.
Pfizer (PFE) agreed to invest $25 million in Monogram Biosciences (MGRM). Pfizer said HIV/AIDS clinical trials for Maraviroc, its investigational CCR5 inhibitor drug candidate, have utilized Monogram's co-receptor tropism assay. Monogram posted a loss of $1.5 million, or a penny per share, for the latest quarter. Revenue rose 33% in the latest three months to $13.2 million from $10 million in the same period a year earlier.